-
NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies
The NCI-MATCH precision medicine clinical trial has reached a milestone with the release of results from several study treatment arms. Findings from three arms were released at the 2018 ASCO annual meeting, adding to findings from one arm released in 2017.
-
New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatments
A novel approach to immunotherapy developed by NCI researchers has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. The findings were published in Nature Medicine.
-
TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy
Findings from the TAILORx clinical trial show chemotherapy does not benefit most women with early breast cancer. The new data, released at the 2018 ASCO annual meeting, will help inform treatment decisions for many women with early-stage breast cancer.
-
NCI study finds gut microbiome can control antitumor immune function in liver
An NCI study in mice that found a connection between gut bacteria and antitumor immune responses in the liver has implications for understanding mechanisms that lead to liver cancer and for potential treatments. The study was published in Science.
-
Annual Report to the Nation: overall cancer mortality continues to decline, prostate cancer mortality has stabilized
The 2018 Annual Report to the Nation on the Status of Cancer finds overall cancer death rates continue to decline and cancer incidence dropped in men and remained stable in women. A companion study reports on recent changes in prostate cancer trends.